The consolidation thesis in Mexican private healthcare is written in the spending data

The investment case for Mexican private healthcare is legible directly from the spending data, and the data is emphatic. The health sector represents 5.2% of GDP, out-of-pocket spending accounts for 49.4% of total health expenditure, the highest share in the OECD, and six of every ten people seek care in private clinics or pharmacies even when they hold public affiliation. Whatever one concludes about those figures as social policy, as a market signal they are unambiguous: Mexicans are already paying for private care, in volume, out of their own pockets. The demand is not the question. The supply side is.

And the supply side is where the opportunity lives, because it is profoundly fragmented. Clinics, laboratories, diagnostic centers, and physician practices operate overwhelmingly as small, independent businesses without the scale to be efficient, to standardize quality, or to command real purchasing power. For the patient, that fragmentation produces uneven quality and opaque pricing. For a long-term investor, it produces one of the clearest consolidation opportunities in the country, of the same species as the roll-up logic that applies to restaurants or logistics, but underpinned by demand that is even more resistant to the economic cycle.

The mechanics of value creation in a healthcare roll-up are specific and worth stating. Consolidating sub-scale providers creates value through multiple arbitrage, since a professionally managed regional platform trades at a materially higher multiple than the individual clinics that compose it. It creates value through procurement leverage on equipment, consumables, and pharmaceuticals. It creates value through shared technology and back-office systems that no single small operator can afford. And it creates value through a brand that patients learn to trust, which in healthcare is among the most durable competitive advantages that exists. The whole becomes worth considerably more than the sum of its parts, and the parts are available because their owners lack the capital to scale.

The risks are real and specific to the sector. Healthcare is regulated, and regulatory compliance and clinical quality control are non-negotiable, because in this industry a lapse is not merely a financial problem. Integration risk is significant, since combining clinical cultures and operating systems is harder than combining, say, warehouses. And the sensitivity of the sector means reputational risk is elevated, which places a premium on governance and on doing the work properly rather than quickly. A healthcare consolidator that cuts the wrong corner does not just impair a return; it harms patients, and the two failures are connected.

Demand, meanwhile, moves in only one direction. A growing middle class, an aging population, and a strained public system push more people toward private care every year. It is a structural, cycle-insensitive need with an evident common-good dimension, which is the combination we look for across the portfolio: solid, durable returns alongside a service that measurably improves people's lives.

Fragmented markets do not organize themselves. Someone has to supply the capital, the operating discipline, and the long-term vision to assemble a regional platform that serves more people, better, than the scattered operators it replaces. Done patiently and properly, that is both a strong return and a genuine contribution.

At MountainStone we build and invest in opportunities like this one. If you operate, or are building, in this space, we would welcome the conversation.